论文部分内容阅读
目的:对新辅助化疗方案在胃癌治疗中取得的疗效探讨分析。方法:选取在我院进行诊治的69例胃癌患者的临床资料,分为观察组患者34例和对照组患者35例,观察组患者予以紫杉醇联合卡培他滨进行新辅助化疗,对照组患者予以DCF方案进行新辅助化疗,均进行3~4个疗程,比较患者化疗前后各指标的变化,综合判断新辅助化疗的临床应用疗效。结果:各胃癌患者经过规范化的新辅助化疗后,观察组34例患者中完全缓解2例(5.88%)、部分缓解23例(67.65%)、疾病稳定6例(17.65%),疾病进展2例(8.82%),对照组35例患者中完全缓解1例(2.86%)、部分缓解12例(37.14%)、疾病稳定10例(28.57%),疾病进展11例(31.43%),观察组新辅助化疗后总有效率(91.18%)明显高于对照组新辅助化疗后的总有效率(48.57%)。结论:新辅助化疗治疗胃癌临床效果良好,且紫杉醇联合卡培他滨疗效更加明显。
Objective: To investigate the effect of neoadjuvant chemotherapy regimen in the treatment of gastric cancer. Methods: The clinical data of 69 patients with gastric cancer who were diagnosed and treated in our hospital were divided into observation group (34 cases) and control group (35 cases). Patients in observation group were treated with paclitaxel plus capecitabine for neoadjuvant chemotherapy and control group DCF regimen for neoadjuvant chemotherapy, were 3 to 4 courses of chemotherapy before and after comparing the changes in various indicators, a comprehensive assessment of the clinical effect of neoadjuvant chemotherapy. Results: After treatment with neoadjuvant chemotherapy, the patients in the observation group achieved complete remission in 2 patients (5.88%), partial remission in 23 patients (67.65%), stable disease in 6 patients (17.65%), and disease progression in 2 patients (8.82%). In the control group, 1 patient (2.86%) was completely relieved in 35 patients, 12 patients (37.14%) were partially relieved, 10 patients (28.57%) were stable, 11 patients (31.43% The total effective rate (91.18%) after adjuvant chemotherapy was significantly higher than that of the control group after neoadjuvant chemotherapy (48.57%). Conclusion: Neoadjuvant chemotherapy has a good clinical effect in treating gastric cancer, and the effect of paclitaxel combined with capecitabine is more obvious.